Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/28/2025

Infectious Disease Screening for Living Kidney Donors

Standard Screening Requirements

  • The American Journal of Kidney Diseases recommends that all living kidney donors require baseline infectious disease screening, including HIV, HBV, HCV, CMV, EBV, and syphilis testing, regardless of travel history 1, 2, 3
  • Urinalysis to detect asymptomatic urinary tract infections should be performed as part of the standard screening 2, 3
  • Testing must be performed within 28 days of donation to ensure accuracy 3

Additional Screening for Central American Travel

  • Living kidney donors traveling to Guatemala and Belize should undergo additional screening for endemic infections, including parasitic, mycobacterial, and fungal infections, with testing performed within 28 days of donation 3
  • The American Journal of Kidney Diseases suggests considering malaria testing if visiting rural areas, as well as arbovirus testing if symptomatic 1, 3

Timing Considerations

  • Screening should be performed after return from travel, allowing at least 2-4 weeks between return from travel and planned donation surgery 4
  • Testing for HIV, HBV, and HCV must be current within 28 days of donation 3

Risk Assessment and Management

  • The transplant team must weigh risks and benefits of proceeding with donation if potentially transmissible infections are found 3

Documentation Requirements

  • Document all travel history, including specific regions visited within Guatemala and Belize, as well as dates of travel and return 3, 4
  • Record all screening tests performed and results 3

Common Pitfalls to Avoid

  • Inadequate timing of testing may miss infections in incubation period, and overlooking the window period may result in undetectable infections 3, 4
  • Neglecting to consult with infectious disease specialists can lead to inadequate testing and increased transmission risks 3